<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567786</url>
  </required_header>
  <id_info>
    <org_study_id>Plasma versus Plasmalyte</org_study_id>
    <nct_id>NCT02567786</nct_id>
  </id_info>
  <brief_title>Fresh Frozen Plasma and Plasmalyte ® for Priming Cardiopulmonary Bypass in Infants and Children</brief_title>
  <official_title>Comparison of Fresh Frozen Plasma and Plasmalyte ® for Priming Cardiopulmonary Bypass in Infants and Children Undergoing Open-heart Surgery: A Double-blind Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <brief_summary>
    <textblock>
      Coagulation abnormalities after pediatric open-heart surgery are complex and very often
      multifactorial. Besides the cardiopulmonary bypass (CPB), the congenital pathology and the
      coagulation tests during CPB, the younger age has been the most significant risk factor for
      bleeding and transfusion requirements. In children the volume of pump priming is much higher
      compared with the patient's circulating blood volume. For this reason the CPB tubing system
      is primed with packed red blood cells and fresh frozen plasma (FFP) to avoid excessive
      hemodilution and induced coagulopathy. While this is routinely performed in neonates and
      small infants, the routine priming of CPB system with FFP has been questioned in several
      randomized prospective studies in older infants. However, the results of these studies are
      conflicting. Moreover, they show methodological issues.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative bleeding (mL blood in the chest tubes). Significant postoperative bleeding is defined as a bleeding of &gt; 5ml/kg/h in the first 6hours postoperatively.</measure>
    <time_frame>The first 6 hours postoperatively</time_frame>
    <description>The exact amount of blood loss in the postoperative period per kilogram weight of child.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Increased risk of of donor exposure intraoperatively and postoperatively.</measure>
    <time_frame>The first 6 hours postoperatively</time_frame>
    <description>The total number of different packs of allogeneic blood products administered per child.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of transfused allogenic blood products (mL).</measure>
    <time_frame>The first 6 hours postoperatively</time_frame>
    <description>The total volume of allogeneic blood products per kilogram weight of child.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Rotem and Multiplate between both groups.</measure>
    <time_frame>The first 6 hours postoperatively</time_frame>
    <description>The results of the point-of-care tests ROTEM and Multiplate will be compared between children in the Plasmalyte group and children in the Fresh Frozen Plasma group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Fresh Frozen Plasma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The priming of the CPB oxygenator will be done with 15 ml/kg of FFP in addition to packed red blood cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasmalyte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The priming of the CPB oxygenator will be done with 15 ml/kg of Plasmalyte in addition to packed red blood cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery with CPB</intervention_name>
    <arm_group_label>Fresh Frozen Plasma</arm_group_label>
    <arm_group_label>Plasmalyte</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fresh Frozen Plasma</intervention_name>
    <arm_group_label>Fresh Frozen Plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plasmalyte</intervention_name>
    <arm_group_label>Plasmalyte</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children weighing between 7 and 15 kg and admitted to undergo open-heart surgery with
             CPB

        Exclusion Criteria:

          -  Patients with preoperative coagulation abnormalities

          -  Parental refusal

          -  Emergency surgery

          -  Patients with preoperative renal or hepatic dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>70 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona Momeni, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Catholique de Louvain; Cliniques Universitaires Saint Luc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mona Momeni</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 29, 2015</study_first_submitted>
  <study_first_submitted_qc>October 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <last_update_submitted>December 4, 2018</last_update_submitted>
  <last_update_submitted_qc>December 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Mona Momeni, MD, PhD</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

